Équilibre BioPharmaceuticals Corp.

Équilibre BioPharmaceuticals' lead asset, EQU-001, is confirmed via ClinicalTrials.gov and a 2025 Epilepsy Research paper (PMID: 41275582) to be ivermectin — a decades-old, off-patent antiparasitic drug — repurposed as an anticonvulsant. This is corroborated independently by a 2023 CNS Drugs review of the epilepsy pipeline (PMID: 37603261), which explicitly names ivermectin as 'an antiparasitic drug currently investigated in a randomised double-blind trial in focal epilepsy,' matching Équilibre's Phase 2 program (NCT05473442) for adjunctive treatment of focal onset seizures, alongside a completed healthy-volunteer PK study (NCT05004571) and a Phase 1 dose-ranging exploratory efficacy study (NCT05063877). Mechanistically, ivermectin's anticonvulsant activity is attributed primarily to positive allosteric modulation of GABA-A receptors, with secondary effects at glycine receptors and glutamate-gated chloride channels — the same broad mechanistic class already exploited by benzodiazepines, barbiturates, and vigabatrin. This is not a first-in-class mechanism. Independent animal studies from different groups (Trailović & Varagić 2008, PMID: 17308985; Dawson et al. 2000, PMID: 11082440; Chern et al. 2025, PMID: 41275582) support anticonvulsant activity across several seizure models, including infantile epileptic spasms syndrome, which is a meaningful and relatively under-served niche. Notably, the Dawson et al. paper flags that anticonvulsant efficacy and CNS toxicity of avermectins both correlate with GABA-A activity, raising a legitimate translational concern about therapeutic window that investors should probe. On the commercial side, the core challenge is that ivermectin is an off-patent generic manufactured cheaply and globally, and marketed for parasitic disease, scabies, and (controversially) repurposed off-label by patients for other indications. No patents specific to an ivermectin epilepsy formulation were identified in this review, meaning Équilibre's defensibility likely rests on method-of-use claims, novel dosing/PK formulations, or regulatory exclusivity (e.g., a 505(b)(2) pathway with orphan designation for IESS) rather than composition-of-matter protection. This is a material commercial risk: even with positive Phase 2/3 data, physicians and payers may question paying premium branded pricing for a drug perceived as a cheap generic, and off-label prescribing could undermine the exclusivity window. Overall, Équilibre occupies a scientifically reasonable but commercially exposed position: it is running real, well-designed multinational Phase 2 trials on a drug with a plausible, multiply-validated (in animals) anticonvulsant mechanism and an established human safety record from other indications, which reduces certain translation risks. However, the mechanism is not novel, the IP position looks thin, and the underlying compound's genericity is a structural commercial headwind that is unusual to see in a well-funded clinical-stage biotech. The regulatory pathway (repurposed approved drug, new indication) is well precedented but the company will need a very clear value proposition (proprietary formulation, orphan exclusivity, novel patient population such as IESS) to justify commercial viability beyond what compounding pharmacies or off-label use could offer.